Related references
Note: Only part of the references are listed.Pasireotide (SOM230) Demonstrates Efficacy and Safety in Patients with Acromegaly: A Randomized, Multicenter, Phase II Trial
S. Petersenn et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Tumor Volume of Growth Hormone-Secreting Pituitary Adenomas during Treatment with Pegvisomant: A Prospective Multicenter Study
Jan-Hendrik Buhk et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
A Consensus on Criteria for Cure of Acromegaly
A. Giustina et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients
S. J. C. M. M. Neggers et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2009)
Guidelines for Acromegaly Management: An Update
S. Melmed et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Somatostatin analog and pegvisomant combination therapy for acromegaly
Sebastian J. C. Neggers et al.
NATURE REVIEWS ENDOCRINOLOGY (2009)
Clinical use of cabergoline as primary and adjunctive treatment for acromegaly
V. J. Moyes et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2008)
Quantitative analysis of somatostatin receptor subtypes (1-5) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR
Giselle F. Taboada et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2008)
A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly
Robert D. Murray et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Preoperative octreotide treatment in newly diagnosed acromegalic patients with macroadenomas increases cure short-term postoperative rates: A prospective, randomized trial
Sven M. Carlsen et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
Pasireotide (SOM230): Development, mechanism of action and potential applications
Herbert A. Schmid
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2008)
A 12-month randomized crossover study on the effects of Lanreotide Autogel and Octreotide long-acting repeatable on GH and IGF-I in patients with acromegaly
Magdalene Andries et al.
CLINICAL ENDOCRINOLOGY (2008)
Efficacy of a slow-release formulation of lanreotide (Autogel® 120 mg) in patients with acromegaly previously treated with octreotide long acting release (LAR):: an open, multicentre longitudinal study
C. L. Ronchi et al.
CLINICAL ENDOCRINOLOGY (2007)
Treatment of acromegaly with the GH receptor antagonist pegvisomant in clinical practice: Safety and efficacy evaluation from the German Pegvisomant Observational Study
I. Schreiber et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2007)
Medical progress: Acromegaly
Shlomo Melmed
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Effects of the long-acting somatostatin analogue Lanreotide Autogel on glucose tolerance and insulin resistance in acromegaly
B. Steffin et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2006)
Presurgical treatment with somatostatin analogs in patients with acromegaly:: effects on the remission and complication rates
M Losa et al.
JOURNAL OF NEUROSURGERY (2006)
Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly: A prospective study in 99 patients
Annamaria Colao et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2006)
Mapping of somatostatin receptor types in GH or/and PRL producing pituitary adenomas
E Thodou et al.
JOURNAL OF CLINICAL PATHOLOGY (2006)
Transsphenoidal microsurgery for newly diagnosed acromegaly: A personal view after more than 1,000 operations
Dieter K. Luedecke et al.
NEUROENDOCRINOLOGY (2006)
The cost of medical care for the acromegalic patient
Robert Knutzen et al.
NEUROENDOCRINOLOGY (2006)
Long-acting somatostatin analog therapy of acromegaly: A meta- analysis
PU Freda et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
CLINICAL REVIEW: A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly
S Melmed et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy
P Jaquet et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2005)
Presurgical octreotide treatment in acromegaly:: no improvement of final growth hormone (GH) concentration and pituitary function.: A long-term case-control study
U Plöckinger et al.
ACTA NEUROCHIRURGICA (2005)
Clinical review: The antitumoral effects of somatostatin analog therapy in acromegaly
JS Bevan
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical 'cure'
P Nomikos et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2005)
The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LAR
SG Ashwell et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2004)
Efficacy of Sandostatin® LAR® (long-acting somatostatin analogue) is similar in patients with untreated acromegaly and in those previously treated with surgery and/or radiotherapy
J Ayuk et al.
CLINICAL ENDOCRINOLOGY (2004)
Systemic complications of acromegaly: Epidemiology, pathogenesis, and management
A Colao et al.
ENDOCRINE REVIEWS (2004)
Efficacy and tolerability of lanreotide autogel therapy in acromegalic patients previously treated with octreotide LAR
O Alexopoulou et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2004)
Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment
Roberto Baldelli et al.
CLINICAL ENDOCRINOLOGY (2003)
Transsphenoidal surgery for acromegaly in Wales: Results based on stringent criteria of remission
P De et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2003)
Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly
C Beauregard et al.
CLINICAL ENDOCRINOLOGY (2003)
Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells
A Saveanu et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2002)
Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist
AJ van der Lely et al.
LANCET (2001)
Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly
A Colao et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2001)
Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant
PJ Trainer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Receptors for dopamine and somatostatin: Formation of hetero-oligomers with enhanced functional activity
M Rocheville et al.
SCIENCE (2000)
Share Paper
